Objective: To investigate the efficacy and immune function of thyroid stimulating hormone (TSH) suppression therapy in postoperative thyroid cancer patients. Methods: Sixty thyroid cancer patients admitted from July 2020–July 2022 were recruited and randomly divided into two groups. The control group (30 patients) received hormone replacement therapy, while the study group (30 patients) received TSH suppression therapy. The thyroid function, clinical efficacy, immune function, and tumor markers of the two groups were compared. Results: After treatment, the levels of free triiodothyronine (FT3) and thyroxine (FT4) in both groups increased significantly, while TSH levels decreased significantly. Moreover, the magnitude of change in the study group was greater than that in the control group (P < 0.05). The total effective rate in the study group was significantly higher as compared to the control group (P < 0.05). After treatment, the levels of CD3+ and CD4+ cells in both groups of patients increased significantly, with the study group showing significantly higher levels than the control group, whereas the level of CD8+ cells decreased significantly, with the study group having lower levels than the control group (P < 0.05). After treatment, the levels of Tg and CEA in both groups were significantly lowered as compared to before treatment, and the levels of Tg and CEA in the study group were significantly lower than the control group (P < 0.05). Conclusion: TSH suppression therapy in postoperative thyroid cancer patients can improve thyroid function, suppress the levels of tumor markers, and enhance immune function, thereby achieving good clinical outcomes.
Zhang J, Chen C, Yang Y, et al, 2022, Diagnosis and Treatment of Postoperative Persistent/Recurrent Cervical Lymph Nodes Metastases in Differentiated Thyroid Cancer. International Journal of Radiation Medicine and Nuclear Medicine, 46(11): 692–696.
Ma Y, Yang S, Wang YQ, et al, 2023, Research Progress in Changes of Hormone Levels of Patients with Differentiated Thyroid Carcinoma During Pregnancy and Their Effects on Occurrence and Development of Disease. Journal of Jilin University (Medicine Edition), 49(3): 811–815.
Xu FZ, Jiang CY, Yi DD, et al, 2023, Influence of Gender-Related Factors on the Occurrence and Development of Thyroid Cancer. Journal of Southeast University (Medical Science Edition), 42(1): 154–159.
Yuan NH, Wei P, Liu SL, et al, 2021, Diagnostic Value of Sound Velocity Matching Technique in Thyroid Carcinoma. Imaging Science and Photochemistry, 39(2): 219–223.
Huang JY, Dai QJ, Su J, et al, 2021, Choice of 131 I Ablation in Patients with Differentiated Thyroid Cancer after Partial Thyriodectomy. Journal of Cancer Control and Treatment,34(2): 143–149.
Zhao FL, Kang YL, Ma YJ, et al, 2021, Effect of TSH Suppression Therapy in Elderly Patients with Thyroid Cancer After Total Thyroidectomy and on Serum Tg, TSH, CEA Levels. The Practical Journal of Cancer, 36(12): 1970–1973.
Wang X, Zhao F, Yan S, 2022, Effect of TSH Inhibition Therapy on Bone Metabolism, CD44v6, and sIL-2R Levels in Patients with Differentiated Thyroid Carcinoma, China Journal of Modern Medicine, 32(23): 34–38.
Yue X, Luo Z, Zhu XY, 2023, Diagnostic Value of Serum Tg and TSH in Preoperative N Staging of Thyroid Carcinoma. Chinese Journal of Laboratory Diagnosis, 27(5): 529–532.
Zhang LD, Xi YC, You LQ, et al, 2018, Effects of TSH Inhibition After Total Thyroidectomy on Tg, VEGF, TSGF, CD44V6, slL-2R and T Lymphocyte Subsets in Patients with Differentiated Thyroid Carcinoma. Journal of Hainan Medical University, 24(2): 242–245.
Wu WJ, Jing JM, Gao JQ, et al, 2022, Effects of TSH Suppression Therapy on TRAb, TPOAb, and TgAb in Patients After Surgery for Differentiated Thyroid Carcinoma. Chinese Journal of Gerontology, 42(6): 1340–1342.
Gao JQ, Wang J, Miao YX, et al, 2020, The Effect of Thyroid Stimulating Hormone Inhibitory Therapy on Prognosis and Serum CD44 V6 Level in Elderly Patients with Thyroid Carcinoma. Journal of North Sichuan Medical College, 35(5): 863–865 + 871.
Wang Y, Pan ZY, Lin ZG, 2018, Effects of TSH Suppression Therapy on Immune Function and Serum CD44V6, FT3, and FT4 Levels in Elderly Patients with Thyroid Cancer. Chinese Journal of Gerontology, 38(5): 1110–1113.
Qian WW, 2019, The Role of TSH Suppression Therapy in the Treatment of Thyroid Cancer and Its Influence on Adverse Reactions in Patients. World Latest Medicine Information (Electronic Version), 19(34): 58 + 60.
Wang X, Zhao YZ, 2021, Analysis of the Effect of TSH Inhibition on Prognosis and T Cell Immune Factors in Elderly Patients with Thyroid Cancer. Chinese Journal of Practical Internal Medicine, 41(11): 978–980.
Wen F, Lu P, Qin CL, et al, 2019, Effects of Atorvastatin Calcium Tablets Combined with TSH Inhibition Therapy on the Efficacy, Blood Lipid Level and Coagulation Function of Patients with Senile Thyroid Cancer After Operation and Hyperlipidemia. Journal of Hunan Normal University (Medical Science), 16(6): 120–123.
Zhang J, Ren HZ, Guo YY, 2022, Relationship between BRAF V600E Mutation and L-T4 Dosage Required for TSH Inhibition Treatment Reaching the Standard After Operation in Patients with Thyroid Papillary Carcinoma. Shandong Medical Journal, 62(32): 37–40.
Mei Y, Wang Q, Zhao LW, et al, 2023, Effects of TSH Inhibition Therapy on Immune Function and Bone Metabolism after Operation in Patients with Differentiation Thyroid Cancer. Chongqing Medicine, 21(6): 686–689.
Zhang XJ, Li FG, Ma YQ, et al, 2023, Effects of Hormone Replacement Therapy on Alanine Aminotransferase, Free Thyroxine, Thyroid Stimulating Hormone Levels and Immune Function in Postoperative Patients with Thyroid Cancer. Oncology Progress, 21(6): 686–689.
Guo YX, Sun XD, Qiang W, et al, 2022, Effect of Helicobacter pylori Infection on Standard Dose of Postoperative Thyrotropin Suppression Therapy for Differentiated Thyroid Cancer. Chinese Journal of Endocrine Surgery, 16(3): 299–302.
Qiu HJ, Fang SY, Luo JG, et al, 2018, Effect of TSH Suppressive Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Carcinoma. Zhejiang Medical Journal, 40(12): 1320–1323 + 1327.